心型脂肪酸结合蛋白与肺动脉高压的相关性临床研究

Abstract
Figure/Table
References (15)
Related Citation (10)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical correlation between heart fatty acid binding protein(H-FABP)and pulmonary arterial hypertension(PAH).Methods Ninety patients with PAH admitted to our hospital from April 2016 to April 2017(without distinguishing the type of pulmonary hypertension)were selected and divided into experimental group and control group.the experimental group was divided into light,medium and heavy subgroups according to the pulmonary artery pressure.Chronic thrombotic PAH,hypoxemia PAH and left heart disease-related PAH were classified according to etiology.The control group was 80 cases of health examination in the same period.H-fabp content in serum of patients was determined by double antibody sandwich ELISA,and creatine kinase isoenzyme(ckmb),troponin I(ctni),nt-pro BNP levels were detected and analyzed statistically.The follow-up time was 18 months and all-cause mortality was counted.Results The levels of H-FABP in PAH patients were significantly higher than those in healthy controls(P＜0.05).CKMB and cTNI showed no significant difference after inter-group comparison(P＞0.05).There was no significant difference in H-FABP levels among PAH patients in different etiologies(P＞0.05).After 1 year follow up visits,H-FABP was associated with all-cause mortality(P＜0.01).Conclusion PAH patients have high H-FABP level which can be used to evaluate the risk of pulmonary arterial pressure.H-FABP is an independent risk factor for all-cause mortality.

Key words： Heart fatty acid binding protein Pulmonary arterial hypertension Degree of risk All-cause mortality

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yu-hong
	LI Min
	LI Wei

Cite this article:

WANG Yu-hong,LI Min,LI Wei. Clinical study of the correlation between heart fatty acid binding protein and pulmonary arterial hypertension[J]. 中国当代医药, 2018, 25(11): 32-34.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I11/32

[1]	Gururajan P，Gurumurthy P，Nayar P，et al.Heart fatty acid bindingprotein（H-FABP）asadiagnosticbiomarkerin patients with acute coronary syndrome[J].Heart Lung Circ，2010，19（11）：660-664.
[2]	Nursalim A，Suryaatmadja M，PanggabeanM.Potential clinical application of novel cardiac biomarkers for acute myocardial infarction[J].Acta Med Indones，2013，45（3）：240-250.
[3]	Rebecca L，Smathers，Dennis R Petersen.The human fatty acid-binding protein family：Evolutionary divergences and functions[J].Hum Genomics.2011，5（3）：170-191.
[4]	Ma X，Ren X，Han P，et al.SiRNA against Fabp5 induces 3T3-L1 cells apoptosis during adipocytic induction[J].Mol Biol Rep，2010，37（8）：4003-4011.
[5]	王勇，柳志红.心型脂肪酸结合蛋白在心肺疾病中的研究进展[J].心血管病学进展，2010，31（3）：367-369.
[6]	Schermuly PT，Ghofrani HA，Wilkins MR，et al.Mechanisms of disease：pulmonary arterial hypertension[J].Nat Rec Cardiol.2011，8（8）：443-455.
[7]	李建生，王明航，余学庆.评估慢性阻塞性肺疾病病情和疗效的指标研究[J].中国老年学杂志，2010，30（1）：118-121.
[8]	张欢，华毛，冯喜英，等.脑钠肽、低氧诱导因子-1α、心肌型脂肪酸结合蛋白在高原肺动脉高压中的研究进展[J].中华肺部疾病杂志（电子版），2017，10（5）：604-607.
[9]	Mauritz GJ，Rizopoulos D，Groepenhoff H，et al.Usefulness of serialN-terminalpro-B-typenatriureticpeptidemeasurements for determining prognosis in patients with pulmonary arterial hypertension[J].Am J Cardiol，2011，108（11）：1645-1650.
[10]	Belly MJ，Tiede H，Morty RE，et al.HbAlc in pulmonary arterial hypertension：a marker of prognostic relevance?[J]Heart Lung Transplant，2012，31（10）：1109-1114.
[11]	Taguchi H1，Kataoka M，Yanagisawa R，et al.Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy[J].Circ J，2012，76（6）：1494-1500.
[12]	Bajaj A，Rathor P，Sehgal V，et al.Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein：A meta-analysis[J].J Crit Care，2015，30（5）：1151-1157.
[13]	Lankeit C，Dellas A，Panzenbock A，et al.Heart-type fatty acid-binding protein for risk assessment of chornic throm boembolic pulmonary hypertension[J].Eur Respir J，2008，31（5）：1024-1029.
[14]	Naito A，Tanabe N，Jujo T，et al.Pentraxin3 in chronic thromboembolic pulmonary hypertension：a new biomarker for screening from remitted pulmonary thromboembolism[J].PLoS One，2014；9（11）：e113086.
[15]	王吉耀，廖二元.内科学（八年制）[M].第 3 版，北京：人民卫生出版社，2015，124-125.